Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comprehensive tumor profiling-guided therapy in rare or refractory solid cancer: A feasibility study in daily clinical practice.

Bulletin du cancer - 1 Apr 2020

Ibrahim Tony, Ahmadie Abir, Rassy Elie, Karak Fadi El, Hanna Colette, Farhat Fadi, Kattan Joseph, Ghosn Marwan

Abstract excerpt

Tumor profiling has been shown to benefit patients with rare or refractory metastatic cancer, but several limitations hamper its use in daily clinical practice. We aim to assess the added benefit of a comprehensive tumor profiling, including factors predictive of response to targeted and cytotoxic therapy, in the treatment of refractory or rare solid tumors outside of a formal clinical trial. Patients were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Decision-Making
Share to Feasibility Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to In Situ Hybridization

Share to Molecular Targeted Therapy

Share to Probability

Share to Progression-Free Survival

Share to Protein Array Analysis

Share to Rare Diseases

Source

Identifiers

PMID: 32145962
DOI: 10.1016/j.bulcan.2019.12.010

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comprehensive tumor profiling-guided therapy in rare or refractory solid cancer: A feasibility study in daily clinical practice.PMID 32145962Read ↗

The landscape of drug sensitivity and resistance in sarcomaSemantic proximity Read ↗

Incorporating tumor genomic profiling and drug screening through circulating tumor cell- derived organoids into clinical practice for the management of Gastrointestinal CancersSemantic proximity Read ↗

First report: PLATFORM study for precision treatment of rare tumors in China.Semantic proximity Read ↗

The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIF Italian Scientific SocietiesSemantic proximity Read ↗

Genomic profiling and expanded use of targeted anticancer drugs in solid cancers with exhausted evidence-based treatment options: the PRECODE study protocolSemantic proximity Read ↗

How many molecular subtypes? Implications of the unique tumor principle in personalized medicine.Semantic proximity Read ↗

Insights of Clinical Significance From 109 695 Solid Tumor Tissue-Based Comprehensive Genomic Profiles.Semantic proximity Read ↗

The landscape of drug sensitivity and resistance in sarcomaSemantic proximity Read ↗

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.Semantic proximity Read ↗

Integrative pan-cancer genomic and transcriptomic analyses of refractory metastatic cancerSemantic proximity Read ↗

Assessing the Impact of Comprehensive Genomic Profiling on Therapeutic Selection for Advanced Solid Tumors in PortugalSemantic proximity Read ↗

Prognostic impact of genomically matched therapy for solid cancers using real-world data from a provincial hospital in JapanSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.